Avani Joshi

1.3k total citations
35 papers, 939 citations indexed

About

Avani Joshi is a scholar working on Rheumatology, Immunology and Ophthalmology. According to data from OpenAlex, Avani Joshi has authored 35 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 10 papers in Immunology and 7 papers in Ophthalmology. Recurrent topics in Avani Joshi's work include Psoriasis: Treatment and Pathogenesis (10 papers), Spondyloarthritis Studies and Treatments (9 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Avani Joshi is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (10 papers), Spondyloarthritis Studies and Treatments (9 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Avani Joshi collaborates with scholars based in United States, United Kingdom and Germany. Avani Joshi's co-authors include Martha Skup, Keith A. Betts, Manish Mittal, Andrew D. Dick, April W. Armstrong, Yanjun Bao, Namita Tundia, Jingdong Chao, Matthias Augustin and L. Puig and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Ophthalmology.

In The Last Decade

Avani Joshi

33 papers receiving 922 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Avani Joshi United States 13 397 314 294 192 97 35 939
Bonnie Vlahos United States 23 752 1.9× 1.5k 4.7× 53 0.2× 237 1.2× 80 0.8× 62 1.8k
L T Dooley United States 5 1.1k 2.8× 849 2.7× 17 0.1× 376 2.0× 86 0.9× 5 1.5k
J.M.M. Groenewoud Netherlands 18 174 0.4× 37 0.1× 712 2.4× 58 0.3× 25 0.3× 36 1.0k
İsmail Şimşek Türkiye 16 132 0.3× 340 1.1× 48 0.2× 19 0.1× 26 0.3× 54 697
Pauline Raaschou Sweden 10 187 0.5× 470 1.5× 11 0.0× 84 0.4× 47 0.5× 21 843
Kasper Fjellhaugen Hjuler Denmark 14 386 1.0× 175 0.6× 7 0.0× 206 1.1× 79 0.8× 20 548
May Y. Choi Canada 16 303 0.8× 467 1.5× 11 0.0× 36 0.2× 27 0.3× 78 785
Emek Kocatürk Türkiye 23 452 1.1× 1.2k 3.9× 15 0.1× 535 2.8× 162 1.7× 139 1.6k
D. Adoué France 17 112 0.3× 255 0.8× 12 0.0× 72 0.4× 118 1.2× 75 884
Elsa Vieira‐Sousa Portugal 15 313 0.8× 589 1.9× 17 0.1× 24 0.1× 18 0.2× 53 825

Countries citing papers authored by Avani Joshi

Since Specialization
Citations

This map shows the geographic impact of Avani Joshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avani Joshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avani Joshi more than expected).

Fields of papers citing papers by Avani Joshi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avani Joshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avani Joshi. The network helps show where Avani Joshi may publish in the future.

Co-authorship network of co-authors of Avani Joshi

This figure shows the co-authorship network connecting the top 25 collaborators of Avani Joshi. A scholar is included among the top collaborators of Avani Joshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avani Joshi. Avani Joshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Silverberg, Jonathan I., Hwanhee Hong, Jacob P. Thyssen, et al.. (2022). Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis. Dermatology and Therapy. 12(5). 1181–1196. 39 indexed citations
2.
Shear, Neil H., Keith A. Betts, Ahmed M. Soliman, et al.. (2021). Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. Journal of the American Academy of Dermatology. 85(3). 572–581. 42 indexed citations
3.
Saeki, Hidehisa, et al.. (2020). An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. Journal of Dermatological Treatment. 33(1). 229–239. 5 indexed citations
4.
Augustin, Matthias, Jo Lambert, Elizabeth H. Thompson, et al.. (2020). Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis. JAMA Dermatology. 156(12). 1344–1344. 40 indexed citations
5.
Strand, Vibeke, Keith A. Betts, Manish Mittal, et al.. (2017). Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison. Rheumatology and Therapy. 4(2). 349–362. 21 indexed citations
6.
Suhler, Eric B., Jennifer E. Thorne, Manish Mittal, et al.. (2017). Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis. Ophthalmology. 124(12). 1799–1807. 28 indexed citations
7.
Deodhar, Atul, Manish Mittal, Patrick M. Reilly, et al.. (2016). Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clinical Rheumatology. 35(7). 1769–1776. 70 indexed citations
8.
Betts, Keith A., Jenny Griffith, Yan Song, et al.. (2016). Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis. Rheumatology and Therapy. 3(2). 323–336. 11 indexed citations
9.
Thorne, Jennifer E., Martha Skup, Namita Tundia, et al.. (2016). Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis. Acta Ophthalmologica. 94(5). e331–9. 63 indexed citations
10.
Sheppard, John D., Avani Joshi, Manish Mittal, et al.. (2015). Effect of adalimumab on visual functioning (VFQ-25) in VISUAL-1 trial patients with non-anterior non-infectious uveitis. Investigative Ophthalmology & Visual Science. 56(7). 1723–1723. 2 indexed citations
11.
Dick, Andrew D., Namita Tundia, Rachael Sorg, et al.. (2015). Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 123(3). 655–662. 140 indexed citations
12.
13.
Wendling, Daniel, Avani Joshi, Patrick M. Reilly, et al.. (2014). Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Current Medical Research and Opinion. 30(12). 2515–2521. 61 indexed citations
14.
Rosenberg, Paul B., Dean F. Wong, Jeffrey S. Ross, et al.. (2013). Cognition and Amyloid Load in Alzheimer Disease Imaged With Florbetapir F 18(AV-45) Positron Emission Tomography. American Journal of Geriatric Psychiatry. 21(3). 272–278. 34 indexed citations
15.
Wang, X., et al.. (2012). PMS37 Economic Evaluation Model of Biologic Therapies for Moderate to Severe Psoriatic Arthritis in Germany. Value in Health. 15(7). A446–A446. 1 indexed citations
16.
Carter, John A., Avani Joshi, Satyin Kaura, & Marc Botteman. (2012). Pharmacoeconomics of Bisphosphonates for Skeletal-Related Event Prevention in Metastatic Non-Breast Solid Tumours. PharmacoEconomics. 30(5). 373–386. 7 indexed citations
17.
18.
Joshi, Avani, John A. Carter, Marc Botteman, & Satyin Kaura. (2011). Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom. Clinical Therapeutics. 33(3). 291–304.e8. 12 indexed citations
19.
20.
Joshi, Avani, et al.. (2010). Media coverage of off-label promotion: A content analysis of US newspapers. Research in Social and Administrative Pharmacy. 7(3). 257–271. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bonnie Vlahos Breakdown of academic impact, for papers by L T Dooley Breakdown of academic impact, for papers by J.M.M. Groenewoud Breakdown of academic impact, for papers by İsmail Şimşek Breakdown of academic impact, for papers by Pauline Raaschou Breakdown of academic impact, for papers by Kasper Fjellhaugen Hjuler Breakdown of academic impact, for papers by May Y. Choi Breakdown of academic impact, for papers by Emek Kocatürk Breakdown of academic impact, for papers by D. Adoué Breakdown of academic impact, for papers by Elsa Vieira‐Sousa
Rankless by CCL
2026